Hemosiderosis

Conditions in which there is a generalized increase in the iron stores of body tissues, particularly of liver and the MONONUCLEAR PHAGOCYTE SYSTEM, without demonstrable tissue damage. The name refers to the presence of stainable iron in the tissue in the form of hemosiderin.

Also Known As:

Networked: 503 relevant articles (19 outcomes, 29 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Seizures (Absence Seizure)
2.	Iron Overload
3.	Anemia
4.	Neoplasms (Cancer)
5.	Liver Cirrhosis (Hepatic Cirrhosis)

Experts

1.	Vichinsky, Elliott: 6 articles (09/2017 - 01/2005)
2.	Rostoker, Guy: 4 articles (01/2019 - 10/2012)
3.	Origa, Raffaella: 3 articles (01/2022 - 07/2006)
4.	El-Beshlawy, Amal: 3 articles (12/2019 - 04/2010)
5.	Elalfy, Mohsen: 3 articles (12/2019 - 04/2010)
6.	Cappellini, Maria Domenica: 3 articles (04/2010 - 07/2006)
7.	Neufeld, Ellis J: 3 articles (01/2010 - 10/2008)
8.	Liang, R: 3 articles (10/2009 - 12/2007)
9.	Tam, S: 3 articles (10/2009 - 12/2007)
10.	Forni, Gian Luca: 3 articles (04/2008 - 07/2006)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Hemosiderosis:

1.	IronIBA 09/01/2008 - "Hepatic hemosiderosis along with serum iron markers improved greatly in the representative patient. " 09/01/1991 - "Methods for evaluating iron stores and efficacy of chelation in transfusional hemosiderosis." 04/28/1984 - "In contrast, joint involvement did not correlate with parameters of iron metabolism or severity of hemosiderosis of other organs, and was not relieved by phlebotomy. " 07/01/2023 - "Hemosiderosis consists of an iron deposit in tissues, which does not cause organic damage to them. " 06/01/2022 - "A RETROSPECTIVE STUDY OF HEPATIC HEMOSIDEROSIS AND IRON STORAGE DISEASE IN SEVERAL CAPTIVE AND FREE-RANGING AVIAN SPECIES."
2.	DeferasiroxFDA Link 01/01/2013 - "Deferasirox, when given in doses ≥30 mg/kg, was found to be an effective and safe drug in reducing transfusional hemosiderosis. " 07/01/2006 - "In a phase II study, the tolerability and efficacy of deferasirox were compared with those of DFO in 71 adults with transfusional hemosiderosis. " 09/01/2017 - "Long-term safety and efficacy of deferasirox in young pediatric patients with transfusional hemosiderosis: Results from a 5-year observational study (ENTRUST)." 01/01/2023 - "Hemosiderosis in chronic dialysis patients: Monitoring the response to deferasirox by quantitative hepatic magnetic resonance imaging." 12/01/2019 - "International sentinel site surveillance of patients with transfusional hemosiderosis treated with deferasirox in actual practice setting."
3.	Deferoxamine (Desferal)FDA LinkGeneric 09/12/2018 - "Deferoxamine (DFO) is one of the most commonly used chelation treatments for transfusional hemosiderosis. " 05/01/2007 - "Since 1962, desferrioxamine (deferoxamine, DFO) has been utilized for the treatment of secondary hemosiderosis. " 07/01/1987 - "[Subcutaneous administration of deferoxamine in a patient with panmyelopathy and post-transfusion hemosiderosis]." 11/02/1984 - "[Deferoxamine in hemosiderosis. " 07/01/1982 - "Desferrioxamine in the management of dialysis hemosiderosis."
4.	Ferritins (Ferritin)IBA 01/01/2013 - "Our results show a significant reduction of ferritin levels and improvement of liver hemosiderosis, assessed by means of magnetic resonance imaging T2* (MRI T2*). " 10/26/2022 - "The study aimed to define the best cutoff point of ferritin to screen for cardiac and liver hemosiderosis in these cases. " 12/01/2007 - "We performed a study of magnetic resonance imaging (MRI) assessment of hemosiderosis in the heart (T2/T2*), liver (T2*), pancreas (T2*), and pituitary gland (T2/T2*/SIR) in 20 hemopoietic stem cell transplant (HSCT) recipients (median peak ferritin levels 7615 pmol/L, range 3411 to 33000 pmol/L). " 10/26/2022 - "The likelihood of cardiac hemosiderosis serum ferritin levels below 2027 ng/mL is 17.5%. " 10/26/2022 - "A cutoff point of 2027 ng/mL for ferritin showed a sensitivity of 50%, specificity 77.4%, PPV 42.1%, and NPV 82.5% for cardiac hemosiderosis (area under curve [AUC] 0.66, 95% CI 0.60-0.71, adjusted odds ratio [OR] 2.05, 95% CI 1.05-4.01). "
5.	Chelating AgentsIBA 03/01/2014 - "This is the first official report of simultaneous daily administration of the two iron chelators DFX and DFO that demonstrates the beneficial effect of the combination on heart and liver hemosiderosis. " 05/01/2007 - "Deferasirox (DSX) is a recently developed oral chelator which shows good efficacy and tolerability in patients with transfusional hemosiderosis due to various underlying disorders. " 09/01/1996 - "[Comparative evaluation of two models of hemosiderosis for analysis of iron chelators]." 01/01/1979 - "A large-scale systematic evaluation of potential iron chelators for the treatment of hemosiderosis was conducted. " 11/01/2002 - "Secondary to the blood transfusions, patients developed severe hemosiderosis that can cause death in the early twenties unless appropriate iron chelator therapy is given. "
6.	HematinicsIBA 10/01/2012 - "Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study." 01/01/2023 - "Hemosiderosis of chronic dialysis has always been a frequent phenomenon in dialysis; formerly related to blood transfusions before the advent of Erythropoiesis Stimulating Agents (ESA), it is currently in connection with the use of massive doses of injectable iron, to ensure the full therapeutic efficacy of ESA. "
7.	ErythropoietinFDA Link 02/01/2016 - "These results indicate that increases in splenic hemosiderosis and the membrane fragility of RBC might be associated with erythropenia and that hepatic production of erythropoietin might contribute to maintaining the blood Hgb concentration in HPK rats. " 01/01/1991 - "Successful treatment of hemosiderosis with regular phlebotomy and recombinant human erythropoietin. " 05/01/1992 - "Two hemodialysis patients with hemosiderosis were treated with combined erythropoietin and repeated phlebotomy. " 01/01/1993 - "Management of hemosiderosis complicated by coexistent anemia with recombinant human erythropoietin and phlebotomy." 01/01/1988 - "Treatment of a seven-year-old child with end-stage renal disease and hemosiderosis by recombinant human erythropoietin."
8.	Adrenal Cortex Hormones (Corticosteroids)IBA 03/01/2008 - "[Superficial hemosiderosis of the central nervous system improved by corticosteroids]." 08/01/1984 - "Allogeneic bone marrow transplantation (BMT) was carried out on a 5-year-old boy with congenital hypoplastic anemia (CHA), who did not respond to corticosteroids and who was displaying signs of progressive hemosiderosis. " 10/01/2001 - "There are a number of cardiac consequences of malignancy, including radiation heart disease, cardiac hemorrhages, cardiac infection, cardiac adiposity or the corticosteroid-treated heart, cardiac hemosiderosis, and toxicity due to anthracycline chemotherapy."
9.	lipoarabinomannan (LAM)IBA 09/01/2008 - "A case of severe liver cirrhosis with hepatic hemosiderosis that was treated successfully with LAM also is shown as a representative case. " 01/01/2008 - "LAM cell proliferation may obstruct bronchioles, lymph vessels and venules that lead to airflow obstruction, formation of lung cysts, bullas and pneumothoraces, chylothorax, chylous ascites, hemosiderosis and hemoptysis. "
10.	eculizumabFDA Link 03/01/2017 - "Eculizumab treatment improved renal hemosiderosis in a patient with paroxysmal nocturnal hemoglobinuria."

Therapies and Procedures

1.	Therapeutics 01/01/1991 - "These findings provide evidence for the efficacy of rHuEPO in multiple phlebotomy therapy for hemosiderosis and may open new avenues for its clinical application." 04/01/2011 - "Chronic transfusion therapy dramatically reduces but does not eliminate this high risk, and inevitably results in transfusion-related hemosiderosis. " 01/01/1991 - "The authors conclude that an adequate chelating therapy protects against hemosiderosis and thus against endocrine pathologies." 05/15/1966 - "[Etiology and therapy of idiopathic lung hemosideroses]." 11/01/1963 - "[APROPOS OF THE PATHOGENESIS AND THERAPY OF IDIOPATHIC HEMOSIDEROSIS OF THE LUNGS IN CHILDREN]."
2.	Hemispherectomy 02/01/1993 - "None has developed superficial cerebral hemosiderosis often seen following the classical anatomical hemispherectomy. " 09/01/1992 - "It was replaced by the subtotal hemispherectomy which effectively eliminated the late complication of superficial cerebral hemosiderosis but was less successful in controlling seizures. " 04/01/2006 - "The efficacy of anatomical hemispherectomy has been offset to some degree by the fact that up to one third of those operated upon will subsequently develop obstructive hydrocephalus, and the so-called superficial subpial cerebral hemosiderosis, with potentially fatal complications. " 01/01/2019 - "Anatomical hemispherectomy revisited-outcome, blood loss, hydrocephalus, and absence of chronic hemosiderosis." 10/01/2001 - "Modifications to anatomical hemispherectomy have been proposed to reduce the incidence of superficial cerebral hemosiderosis and hydrocephalus while still achieving seizure control. "
3.	Blood Transfusion (Blood Transfusions) 07/19/2021 - "An EUS-guided liver biopsy confirmed a diagnosis hepatic hemosiderosis secondary to long-term blood transfusions. " 01/01/2019 - "Regular blood transfusion leads to hemosiderosis in their main organs. " 06/01/2012 - "A few other features seen in MPDs are caused by extramedullary hematopoiesis, increased hepatic blood flow, and secondary hemosiderosis from multiple blood transfusions. " 10/01/1997 - "In spite of a little amount of blood transfusion, he showed hepatic hemosiderosis. " 04/13/1996 - "Repeat blood transfusions may produce clinically overt organ hemosiderosis, e.g. "
4.	Renal Dialysis (Hemodialysis) 08/01/1984 - "This study suggests that one should be careful in making an early diagnosis of hepatic disease, especially hemosiderosis, in hemodialysis patients based on the hepatic CT absorption value because it is affected by hemodialysis." 07/17/1981 - "Hemosiderosis in hemodialysis patients." 07/25/1980 - "Hemosiderosis in hemodialysis patients. " 05/01/1980 - "Hepatic hemosiderosis in maintenance hemodialysis (MHD) patients." 01/01/1988 - "There have been some reports on the risk of developing hemosiderosis in hemodialysis patients when heavily transfused and simultaneously possessing hemochromatosis alleles (HA). "
5.	Chelation Therapy (Therapy, Chelation) 08/01/2014 - "Chelation therapy is necessary to prevent the consequences of hemosiderosis. " 04/01/1965 - "[New possibilities in chelation therapy for hemosiderosis]." 10/01/2005 - "Although the indications for transfusions in sickle cell syndromes are well listed, and chronic transfusion has become practicable since the recent advances in chelation therapy have essentially eliminated the risk of secondary iron overload, multi-transfused, non-compliant to long-term chelation therapy patients confront the complication of iron overload and secondary hemosiderosis. " 12/01/2013 - "The imaging of pediatric hemoglobinopathies, which is influenced by concomitant hemosiderosis and the sequela of chelation therapy, has evolved over the years along with ever-improving technology. " 10/01/2005 - "Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia."